MAFEIP is a web-based tool with the purpose of estimating the health and economic outcomes of a large variety of social and technological innovations. From the EIP on AHA perspective, MAFEIP represents the key instrument to estimate the impact of EIP on AHA interventions.
MAFEIP enables early impact assessments of an innovative process in the health and care sector. Using this tool can help decision-makers to take informed decisions about the future design of this innovative process or about its deployment on a larger scale (this is the “decision to invest”).
MAFEIP can also help, at a later stage of the innovation development, to assess precisely its value for citizens and other stakeholders (this is the “decision to buy”).
The potential users of the MAFEIP tool are stakeholders in the health and care sectors who are willing to deploy innovative practices to improve quality of care, enhance accessibility or make more efficient use of resources.
The MAFEIP support team continues to provide technical and operational support to all those organisations that wish to use MAFEIP to assess impact and cost-effectiveness of the digital health interventions they are implementing or planning to adopt.
The MAFEIP team is leveraging the breadth of the members’ existing international networks and the multiple connections established through European-funded projects to promote the use of MAFEIP across Europe.
The MAFEIP support team at Open Evidence is committed to disseminating the work of the MAFEIP community. It will increase its outreach through different channels so as to expand engagement with and use of the MAFEIP tool.
Regular reports of MAFEIP outputs will be released when organisations have finished the cost-effectiveness analyses, illustrating the impact on the EIP on AHA activities.
The MAFEIP team is now holding multiple meetings with interested organisations to help them use MAFEIP to evaluate their interventions. This activity is supported by the coordination and support action, WE4AHA.
MAFEIP 2.0 has already been used to develop new use cases, such as the cost-effectiveness analysis performed for the Puglia case study, the Carewell project, i-Prognosis and the Renewing Healthcare project.
Growing public understanding of useful tools andtechniques is crucial. As of August 2020, the MAFEIP community had over 300 members from 27 countries (20 are within the European Union). MAFEIP’s goal is to continue expanding the community throughout 2020 and making public even more use cases. In fact, during the second half of 2020, four additional use cases will be published, and around ten organisations will start the cost-effectiveness analyses for their interventions through MAFEIP.
It is hugely important to analyse the impacts of the 2020 COVID-19 pandemic crisis. Tools like MAFEIP are critical in helping prepare countries and healthcare systems to face potential next waves of infections or pandemics more effectively. MAFEIP could be of great value to evaluate health innovations, allowing for the scale-up of medically impactful and low-cost interventions, and communication about them.